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A B S T R A C T
P-glycoprotein is important in local antibiotic resistance. Aim was to evaluate the role of P-glycoprotein in local anti-
biotic resistance in patients with antral gastritis during antibiotic therapy to Helicobacter pylori infection. In the group
of 53 patients with pathohistologically verified gastritis and microbiologically confirmed H. pylori infection (no signs of
antimicrobial resistance) we have determined P-glycoprotein activity in gastric mucosa biopsy specimens, and compared
them with the P-glycoprotein activity in 12 control subjects with normal endoscopic findings. The H. pylori positive pa-
tients were treated according to Maastricht protocol with short-term 7-day therapy consisting of two antibiotics (amoxi-
cillin and azithromycin/metronidazole and clarithromycin) and a proton pump inhibitor. P-glycoprotein activity was de-
termined in rhodamine dye efflux test and quantified by ratio of the mean fluorescence (RMF) in flow cytometry analysis.
H. pylori was successfully eradicated in the first cycle in 20 patients, whereas therapy was continued in 33 patients. The
mean pre-treatment RMF values were higher in patients with H. pylori infection then in control subjects (p<0.0046).
RMF was also higher in patients with multiple therapeutic failure than in those with successful H. pylori eradication
(p<0.0001). RMF increased significantly during the antibiotic therapy (p<0.05). P-glycoprotein might be one of the
causes of therapy failure in patients with H. pylori. Our study confirms the importance of quantitative evaluation of
P-glycoprotein expression during antibiotic treatment response.
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Introduction
According to the Maastricht Consensus, treatment of
H. pylori infection implies one antisecretory drug and a
combination of two antibiotics1,2. About 10% of H. pylori
treated infections remain positive. Successful H. pylori
eradication depends on numerous factors. The efficacy of
H. pylori eradication has been shown to be influenced by
patient compliance during treatment3, gastric pH4, and
geographic location. Local factors have the role on better
success in eradication, such as coexistence of antral gas-
tritis, gastritis of the gastric body5, and in patients with
peptic ulcer (cagA and vacAs1 positive strains) then in
patients with functional dyspepsia6–8. It should be noted
that the development of primary and secondary bacterial
resistance depends on the length of treatment, combina-
tion of antibiotics, and drug concentration9–10. H. pylori
has developed resistance to many drugs, e.g., metroni-
dazole, clarithromycin, etc.3,7,11. Treatment failure has
been ascribed to metabolic changes in H. pylori itself7,12
and increasing resistance to chemotherapy. Repeat drug
administration at a higher concentration has been dem-
onstrated to produce better result4,10,12, suggesting that
local conditions are responsible for therapeutic success3,12.
The oral bioavailabity or absorption of antibiotics de-
pends on the dosage forms administered, mucosal perme-
ability and absorptive clearence. H. pylori poorly respon-
sive to therapy, may relate MDR expression because
some antibiotics are known transmembrane transport-
ers substrates. A high concentration of multidrug trans-
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porter (P-glycoprotein (Pgp), that actively pumps out all
potentially cytotoxic substances, is found on the gastro-
intestinal tract epithelium. Their mechanism of action is
being based on binding a broad spectrum of drugs to the
membrane polypeptide chain and extruding them to the
surroundings by use of ATP energy. All ATP dependent
efflux proteins belong to the large ABC superfamily13–15
and are homologous in many animal species16. Efflux as a
mechanism of antibiotic resistance was demonstrated for
gram-negative bacteria in the early 1980’s17. The anti-
microbial efflux transporter forH. pylori, LmrA, homolo-




Gastric biopsy specimens were collected from 65 sub-
jects upon their informed consent in writing according to
the Helsinki Declaration and approved by the Hospital
Ethics Committee. Fifty-three patients (24 male and 29
female), mean age 47.4 (range 18–75) years, with endo-
scopically and pathohistologically verified antral gastritis
had H. pylori infection and were treated as outpatients.
Cell cultures
For determination of Pgp activity, exponentially grow-
ing human erythroleukemic K562 cell line with an opti-
mal density of 5x105/mL were prepared as control cells.
The cell lines were grown in an RPMI 1640 nutrient mix-
ture supplemented with 2 mM L-glutamine, 1 mM sodium
pyruvate, 1000 units/mL penicillin, 100 mg/mL strepto-
mycin, and 10% fetal calf serum (FCS) at 37C in a hu-
midified atmosphere of 5% CO2, in air26. Negative con-
trol: drug-sensitive K562 line was purchased from the
ATCC (American Type Culture Collection, Rockville, Mary-
land, USA). Positive control: the resistant HHT/K562 cell
line obtained by continuous exposure to HHT was a kind
gift from Professor J.P. Marie (Hotel Dieu, France) and
was cultured in the presence of 150 ng/mL of HHT.
Chemicals
Rhodamine-123 (Rh123, 2-6-amino 3 imino 3H xan-
thene 9 y benzoic acid methyl ester, Sigma, St. Louis,
MO, USA) is a cationic lipophilic fluorescent dye fre-
quently used to study Pgp activity. The cells were labeled
with 1:100 of stock solution in PBS, a final concentration
20 mg/mL. Non-toxic substrates for Pgp, a fungal metabo-
lite Cyclosporine A (CsA, from Tolypocladium inflantum,
Sandoz Pharmaceuticals, Switzerland) and homoharrin-
gtonine (HHT, an alkaloid from Cephalotaxus hainan-
ensis, Sigma) were used in a final concentration of 2.5
ng/mL and 150 ng/mL, respectively.
Methods
HP Diagnostic studies
The presence of H. pylori was verified by two parallel
tests (microbiology and pathohistology). Histologic diag-
nosis included material staining according to Giemsa21.
Microbiologic diagnosis included isolation and typing.
B-biodisk and Chaves method determined antibiotic sen-
sitivity by E test22–24. Control group had 12 patients with
dyspepsia as an indication for upper gastrointestinal en-
doscopy, in whom H. pylori infection was neither micro-
biologically nor histologically demonstrated21–24. As the
study was not aimed at comparison of different therapeu-
tic protocols, it included a higher proportion of patients
with multiple therapeutic failure than would otherwise be
expected according to the efficacy ofH. pylori eradication.
Treatment of H. pylori infection
All patients underwent standard short-term triple
therapy consisting of pantoprazole (P), a proton pump
inhibitor (PPI), at a dose of 40 mg b.i.d., and two antibi-
otics, according to Maastricht recommendations1,2,9. The
following antibiotics were used: metronidazole (M), 500
mg; amoxicillin (A), 1000 mg; and clarithromycin (C),
500 mg b.i.d. for seven days, in randomized combina-
tions. The patients were randomly allocated to the PAM
(n=39) or PAC (n=14) protocol. Following initial thera-
peutic failure in eradication ofH. pylori infection, the pa-
tients were administered a new combination of the listed
antibiotics for 10 days, or azithromycin (AZ) at a dose of
500 mg s.i.d. for 5 days in addition to one of the listed an-
tibiotics for 10 days1,2,25. So, in the second course after
initial failure with the PAM protocol, there were 15 pa-
tients in the PAC protocol and PAAZ protocol each. Also,
in the second course after initial failure with the PAC
protocol, there were three patients on the PAAZ pro-
tocol1,2,9,25. Following second failure of H. pylori eradica-
tion, a third combination was introduced, consisting of P
40 mg b.i.d., in combination with bismuth citrate (B)
t.i.d., M 500 mg s.i.d., and tetracycline (T) 500 mg q.i.d.
for 14 days1,2,25. This final protocol included 22 patients.
The treatment with pantoprazole, 40 g/day, was continued
for another 6 weeks after each of these protocols1,2,9,25.H.
pylori eradication was simultaneously assessed by micro-
biology and pathohistology 7 weeks of the completion of
each protocol1,2,9. Patients who had been receiving anti-
-inflammatory or MDR dependent drugs (that may have
influenced the efflux) within one year preceding the stu-
dy were not included13–20.
Collection of biopsy specimens
Gastric biopsy specimens for microbiology and histol-
ogy as well as for the assessment of Pgp activity were ob-
tained from the oxyntic area during gastrointestinal en-
doscopy using an Olympus and Pentax endoscopy video
system, in line with recommendations of the Sydney clas-
sification24. Two specimens from the antrum and body of
the stomach each, and one from the angulus were ob-
tained for microbiologic and histologic analysis, whereas
two specimens from the anterior and posterior wall of the
antrum each were obtained for the study of Pgp activity.
Microbiologic and histologic analysis
Density of intraepithelial neutrophils (DIEn) and H.
pylori density (DHP) were determined in biopsy speci-
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mens as sensitive parameters of mucosal lesion and H.
pylori presence24 H. pylori and neutrophil density was
scored 1–4 according to Sydney classification.
Determination of Pap activity
Preparation of gastric biopsy specimens
Upon endoscopy, the gastric biopsy specimens (GBS)
were immediately placed in transport media and then into
transport containers with ice at a constant temperature of
4°C. GBS was dissociated mechanically by mincing the
sample with little scissors, then washed with cold buffer
and centrifuged at 3000 rpm for 5min at 4°C. The viability
and yield were assessed by trypan blue exclusion.
Rhodamine efflux measurement
A direct functional assay for Pgp activity was per-
formed by the Rh123 uptake/retention method (27) ad-
apted for stomach tissue analysis. Briefly, aliquoted GBS
(5–8x105 cells/tube) were stained for 60 min with 5 mL of
Rh123 in the presence or absence of MDR-reversing
agent CsA (5 mL). After Rh123 uptake, cells were washed
and fed with Rh123-free culture medium, cultured for 60
min at 37 °C, again in the presence or absence of CsA to
evaluate its effect on Rh123 efflux (retention). After-
wards, GBS was centrifuged in culture medium, resus-
pended and kept in ice and darkness for 10 min until flow
cytometry analysis. As a reference, K562 and HHT 150/
K562 cells were processed in parallel with the patient
samples. The analysis was performed on an FACS Cali-
bur flow cytometer (Becton Dickinson, San Jose, CA)
equipped with an ultraviolet argon laser (excitation at
488 nm, emission at 530/30 and 570/30 nm band-pass fil-
ters). Analysis of 104 cells per sample was carried out in
log histogram. When Rh123 was being diffused into the
cell, Pgp actively pumped out the fluorochrome, and cel-
lular fluorescence was determined by the rates of influx
and efflux. If another compound, a substrate and/or in-
hibitor, was presented in the same manner together with
Rh123, the efflux was blocked and the fluorescent dye ac-
cumulated in the cell, producing higher mean fluores-
cence intensity (MFI). The result can be quantitatively
analyzed and expressed as the ratio of the two mean
fluorescences (RMF). RMF represents the ratio of MF of
Rh123 with CsA modulator divided by MF of Rh123
without modulator after subtraction of the fluorescence
of the blanks (autofluorescence of cells <1%). As the
amount of intracellular Rh123 dye content upon the ad-
dition of modulator correlated with Pgp activity, RMF ³1
was considered positive.
Variation due to test conditions
Upon endoscopy, GBS was transported at a constant
temperature of 4 °C and analyzed within one hour. Gas-
tric cells were mechanically dissociated by use of small
scissors or by enzymatic digestion (trypsin), whereby the
viability and gain were controlled by trypan blue exclu-
sion. The cells obtained by mechanical dissociation (minc-
ing with scissors) were more numerous and showed
higher viability than those obtained by trypsin enzy-
matic dispersion. In order to assess the impact of storage
on test reproducibility, 12 randomly chosen GBS were di-
vided into two groups. One group was analyzed on the
day of sampling, and the other were stored overnight at
room temperature in 10 mL of cold buffer. The minimal
concentration of GBS was 0.5´105 cells/mL.
Statistics
We used STATISTICA software for the analysis of
variance, multiple regression analysis and ROC analysis
in the interpretation of results. The level of significance
was set at p<0.001. The mean value of the scores ob-
tained on antrum biopsy (anterior and posterior wall/2)
was used for statistical analysis of DIEn and DHP.
Results
The activity of Pgp was measured in gastric biopsy
specimens (GBS) of 53 patients with H. pylori infection
and 12 dyspeptic patients without H. pylori infection
(control group). We have found no diffeterce in age (47.39
vs. 48.33 years) and sex (M/F=5/7 vs. 24/29) between this
two groups.
Measurement of Pap activity in patients with
H. pylori infection
Pgp activity was determined in 53 patients with H.
pylori infection and 12 dyspeptic patients without H.
pylori infection (control group). The intensity of rhoda-
mine dye extrusion by GBS with H. pylori infection was
higher as compared with H. pylori negative control GBS
(0.8±0.30 vs. 1.38±0.66; g=1; F=8.6, p<0.0046). H. pylori
infection stimulated Pgp activity. Based on ROC analysis,
RMF³1 was considered positive.
Antibiotic therapy stimulaed Pgp activity. Irrespec-
tive of therapeutic success in ten randomly chosen H.
pylori positive patients pre- and post-therapeutic Pgp ac-
tivity was assessed. After treatment (7-weeks), stronger
GBS extrusion of rhodamine dye was recorded in 6/10 pa-
tients. Wilcoxon pair test yielded a significant difference
between the pre- and post-therapeutic values (t=9.0;
z=1.885; p<0.05).
Neither is repeat therapy efficacious in
enhanced Pgp activity
The course of therapy was not affected by either age or
sex. The patients requiring multiple courses at H. pylori
eradication (group B, n=33) initially had amore severe in-
fection (higherH. pylori concentration and intraepithelial
neutrophil infiltration), however, neither these variables
were found crucial for course of treatment. Therapeutic
success was influenced by Pgp activity: the patients with
failure of H. pylori eradication had a statistically higher
(p<0.00001) pretherapeutic Pgp activity (1.647±0.65) than
either patients with efficientH. pylori eradication (0.889±
0.28) or control group (0.787±0.29, Table 1).
Other parameters vs. Pgp in H. pylori infection
Multiple regression analysis yielded a significantly
highest beta coefficient for RMF and DIEn (p<0.001).
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ROC analysis demonstrated higher sensitivity, specificity
and accuracy for RMF (90.90%, 71.87% and 81.54%, re-
spectively, for borderline RMF value of 1.0) than for DHP
(48%, 71% and 60%, respectively, for borderline DHP of
score 2), and DIEn (66%, 71% and 69.23% respectively,
for borderline DIEn of score 2).
Combined therapy has no effect in case
of enhanced Pgp activity
The number of patients included in the study was too
small for statistical analysis of each antibiotic group. The
antibiotics used appeared to differ in stimulating Pgp activ-
ity, i.e. the first successful course was for PAM or PAC
(RMF±SD for PAM 0.83±0.3 and for PAC 0.95±0.25) was
less dependent on Pgp activity than the repeat combination
with azithromycin (RMF±SD 1.706±0.62; n=18). The pa-
tients with multiple attempts at H. pylori eradication had
higher pretherapeutic RMF values, however, there was no
significant difference in the choice of antibiotics (between-
-group analysis of variance: f=5.031; p<0.000898).
Factors influencing therapeutic efficacy
There was no significant difference in pretherapeutic
Pgp activity between the patients with ultimately suc-
cessful and unsuccessfulH. pylori eradication (1.26±0.715
vs. 1.54±0.66; p<0.13418, Table 2). As there was no such
difference in other clinical parameters either (age, sex,
DIEn and DHP, p<0.189), it seems that, although influ-
encing the duration and course of treatment, Pgp cannot
be used to predict the ultimate treatment outcome.
Test conditions and Pgp meaurement
The activity of Pgp was measured in gastric biopsy
specimens (GBS) of 53 patients with H. pylori infection
and 12 dyspeptic patients without H. pylori infection
(control group). The two patient groups were matched
according to mean age (47.39 vs. 48.33 years) and sex
(M/F=5/7 vs. 24/29).
In order to assess the impact of storage on test repro-
ducibility, as shown in Table 3, the mean RMF was
1.427±1.034 and 2.521±2.067 on day 1 and 2, respec-
tively. RMF was elevated in most of the samples (10/12; t
test for dependent samples: t=1.932; g=11; p<0.0795;
SIGN test: z=1.443; p<0.148). In the samples with the
addition of modulator, fluorescence varied on day 2 and it
seemed that there was no overexpression of Pgp func-
tion, although the cells were viable. As storage results in
changed drug transport functions, for reasons of cellular
metabolic and membrane integrity it is better to use
fresh cells, within a few hours of sampling.
Discussion
Many questions about the mechanisms of drug failur-
es to cure H. pylori infection the remain to be answered.
The patient compliance, as antimicrobial resistance is
the most important factor determining the outcome of
antibiotic therapy. The increased prevalence of antibiotic-
-resistant H. pylori strains has serious implications28,29.
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TABLE 1
CORRELATION OF ELEVATED PRETHERAPEUTIC PGP ACTIVITY VRS OTHER PARAMETERS
ACCORDING TO NEEDS FOR MULTIPLE THERAPIES
Variables
Tharapy cycle
H. pylori negative H. pylori positive H.pylori positive
NO One=I Two or more=II Pa beta Pb
widctlpar (n=12) (n=20) (n=33)
Age (yrs) 48.3±16.5 47.5±8.8 47.3±13.7 0.973 0.152
Sex (M/ F) 5/7 9/11 15/18 0.975 0.153
DHP 1.0±0.0 2.75±0.91 2.90±0.97 0.00001 0.00065
DIEn 1.0±0.0 2.65±0.81 3.06±0.86 0.00001 0.450
RMF (X±SD) 0.787±0.29 0.889±0.28 1.647±0.65 0.00001 0.000005
NO= no therapyH. pylori positive patients: A = one therapy cycle, B = two or more therapy cycles; M =male; F = female; DHP =H.
pylori density; DIEn = density of intraepithelial neutrophil infiltration; RMF = ratio of mean fluorescences, Pa for analysis of vari-
ance, Pb for multiple regression analysis
TABLE 2
IMPACT OF PRETHERAPEUTIC VALUES ON H. PYLORI
ERADICATION EFFICACY
Variable





Age (yrs) 46.54±12.51 48.54±11.44 0.556
Sex (M/F) 15/16 9/13 0.598
DHP 2.90±0.97 2.77±0.92 0.626
DIEn 2.77±0.846 3.09±0.86 0.189
RMF (X±SD) 1.26±0715 1.54±0.66 0.13418
M = male; F = female; DHP = H. pylori density according to
Sydney criteria; DIEn = density of intraepithelial neutrophil in-
filtration according to Sydney criteria; RMF = ratio of means
The present article speculates about the potential mech-
anism limiting the gastrointestinal availability of antibi-
otics by P-glycoprotein (Pgp) mediated decrease in drug
accumulation. In humans, Pgp is expressed on a wide va-
riety of normal cells. Pgp is especially present in secre-
tory tissues including the liver, intestinal tract epithelia
from jejunum and colon, adrenal cortex, kidney, certain
capillary endothelia, peripheral blood lymphocytes and
hemopoietic precursor cells30. In gastrointestinal tract,
Pgp acts as an ATP-consuming efflux pump extruding
the natural toxins across the epithelial surface to the in-
testine, hepatocytes in biliary canaliculi and small duc-
tules of the pancreas31. In the gastrointestinal tract there
is regional variation in Pgp expression: being maximally
expressed in the epithelial cells of illeum with a gradual
decrease proximally into the jejunum duodenum and
stomach32. Expression of Pgp on the luminal surface of
epithelial cells in gastrointestinal tract suggest a role in
decreasing33, absorption34 and secretion of endogenous
and exogenous amphipathic toxins35.
Recently we have found that several sources reported
about the presence of direct evidence that Pgp inhibits
the gastrointestinal absorption of orally administered
drugs35–39. To the best of our knowledge, this is the first
report analyzing Pgp activity in H. pylori infection. We
evaluated Pgp function in gastric cells from patients with
H. pylori infection by means of intracellular accumula-
tion and efflux of a fluorescent dye. In the GBS loaded
with Rh123 dye an increased efflux was observed in 33H.
pylori positive patients who failed to respond to treat-
ment. The patients with enhanced Pgp activity (RMF
>1.5) failed to respond to either first or second therapy
with the same or another antibiotic. As Pgp activity is
low (RMF<1) in patients who respond favorably to the
first course of treatment, it is of most importance to as-
sess Pgp activity before therapy introduction and to
monitor it before repeat antibiotic cycles. Pgp activity is
generally low at the time of diagnosis, i.e. before the pa-
tient receives any treatment. These findings indicate
that an increased Pgp activity may contribute to the
drug-induced effect on gastric cells long after therapy
completion. Although H. pylori infection per se stimu-
lates Pgp pump activity, this activity seems to addition-
ally rise during the course of disease, because RMF index
is lower at the disease onset. And the last but not the
least, the lower RMF values recorded in patients with re-
mission support the hypothesis that inappropriate thera-
peutic combinations lead to eradication failure. There-
fore, Pgp activity testing might be used as a sign of
therapeutic failure and need of multiple therapeutic pro-
tocols in a particular patient. Although Rh123 efflux
could not predict final outcome of the attempts at H.
pylori eradication, it did show that elevated RMF values
had greater impact on H. pylori eradication failure with
the use of AZ than with other antibiotics. Other parame-
ters ofH. pylori infection (DHP, DIEn) did not prove use-
ful in predicting either the need of an increased number
of therapeutic protocols or the final treatment outcome.
We can sugest pretherapeutic testing of Pgp in H. pylori
infected patients, and repeated measurement of Pgp in
patients with unsucesfull eradication. In this way we will
be able to detect patients who will need repeated thera-
pies, and in those patients antimocrobial in vitro testing
will be needed.
At the end, for those who intend to start measure-
ment of Pgp in gastric cells, we can sugest that storage
results in changed drug transport functions, for reasons
of cellular metabolic and membrane integrity it is better
to use fresh cells, within a few hours of sampling.
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TABLE 3




Rh 123 Rh123+CyA RMF Rh 123 Rh123+CyA RMF
MF MF MF MF
X±SD 102.39±69.96 117.73±77.80 1.42 ±1.034 79.40±90.92 138.65±101.06 2.522±2.067
Confid. -95.00% 57.93 68.30 0.66 21.63 74.43 1.21
Confid. +95.00% 146.84 167.1730 2.02 137.17 202.86 3.8352
Minimum 5.47 17.86000 0.24 17.25 4.28 0.15
Maximum 262.30 225.3500 3.40 308.40 326.90 6.97
Day 1 = fresh cells, several hours of sampling; day 2 = cells stored overnight at room temperature; Rh123 = rhodamine; CyA = cyclo-
sporine A; MF = mean fluorescence; RMF = ratio of mean fluorescence
Day 1 vs. Day 2 results:for Rh123 v < V = 41.44% Z = 0.28 p<0.77; for Rh123+Cy v < V =58.33 Z = 0.28 p<0.77; for RMF v > V =
83.33 Z = 2.02 p<0.043
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VA@NOST ODRE\IVANJA AKTIVNOSTI P-GLIKOPROTEINSKOG PRIJENOSNIKA ZA VI[E
LIJEKOVA U BOLESNIKA S HELICOBACTER PYLORI INFEKCIJOM
S A @ E T A K
P-glikoprotein je va`an ~imbenik u neuspje{nosti lije~enja infekcije antibioticima. Cilj studije bio je istra`iti va`nost
P-glikoproteinskog prijenosnika za vi{e medikamenata u bolesnika s antralnim gastritisom tijekom antibiotske era-
dikacijeke terapije Helicobacter pylori infekcije. U skupini od 53 bolesnika s patohistologijski dokazanim gastritisom i
mikrobiologijski potvr|enom Helicobacter pylori infekcijom, a bez znakova za antimikrobnu rezistenciju, mjerili smo
aktivnost P-glikoproteina u `elu~anoj sluznici dobivenoj nakon biopsije, te smo je uspore|ivali s aktivnos}u P-gliko-
proteina u 12 ispitanika s urednim endoskopskim i patohistologijskim nalazom. Bolesnici s Helicobacter pylori infek-
cijom lije~eni su 7-dnevnom terapijom, a prema protokolu iz Maastrichta, koja se sastojala od dva antibiotika (amoksi-
cilin i azitromicin/metrronidazol i klaritromicin) i inhibitora protonske pumpe. Aktivnost P-glikoproteina odre|ivana je
rhodamine dye efflux testom i kvantificirana je srednjom vrijedno{}u florescencije (RMF), koja je mjerena proto~nim
citometrom. Helicobacter pylori je uspje{no eradiciran u prvom poku{aju u 20 bolesnika, dok je terapija trebala biti
nastavljena u 33 bolesnika. Prije po~etka lije~enja, bila je vi{a srednja vrijedonst RMF-a u bolesnika s Helicobacter
pylori infekcijom nego u kontrolnoj skupini (p<0,0046). RMF je tako|er bio vi{i u bolesnika s vi{estrukim neuspijesima
u eradikadciji Helicobacter pylori infekcije nego u onih s uspje{nom eradikacijom (p<0,0001). RMF je zna~ajno poratao
tijekom antibiotskog lije~enja (p<0,05). Mo`emo zaklju~iti kako P-glikoprotein mo`e biti jedan od uzroka neuspijeha u
eradikaciji H. pylori infekcije. Na{a studija potvr|uje va`nost mjerenja i kvantitativne evaluacije ekspresije P-gliko-
proteina tijekom antibiotske terapije.
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